Brain Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Brain cancer refer to abnormal growth
of brain or central nervous system (CNS) cells. These abnormal cells form a
mass called a tumor, which can interfere with normal brain functions. It can be
primary or secondary. Primary brain tumors originate in the brain and can be
benign or malignant. Benign tumors are noncancerous and grow slowly. They do
not invade nearby tissues and are less likely to recur after treatment.
Malignant tumors, on the other hand, are cancerous and grow rapidly. They
invade surrounding tissues and may recur even after treatment. Secondary brain
tumors originate in different body parts and spread to the brain. Cancer cells
from primary tumors in organs such as the lung, breast, kidney, colon, or
stomach can travel through the bloodstream or lymphatic system and form
secondary tumors in the brain. Approximately 20% of brain cancer cases are due
to brain metastasis. Brain cancer symptoms can vary depending on the location
and size of the tumor. Common symptoms include frequent headaches, seizures,
changes in vision (such as double vision or blurred vision), hearing and speech
problems, difficulty with balance and coordination, cognitive changes, and
personality changes. However, these symptoms can also be caused by other
conditions, so it's important to consult a healthcare professional for an
accurate diagnosis. Brain tumors are classified into grades based on their
growth rate and aggressiveness. The grading system helps determine the
treatment approach and prognosis. High-grade tumors, also known as malignant or
aggressive tumors, grow rapidly and are more likely to spread to other brain or
spinal cord parts. Low-grade tumors, also called benign or slow-growing tumors,
tend to grow more slowly and are less likely to invade surrounding tissues.
Diagnosis of brain cancer typically involves a combination of imaging tests,
such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, and
a biopsy, which involves the removal of a small sample of the tumor for
examination under a microscope. Brain cancer treatment options include surgery,
radiation therapy, and chemotherapy. The choice of treatment depends on various
factors, including the type and grade of the tumor, its size and location, the
patient's age and overall health, and the presence of any genetic mutations or
biomarkers. In 2023, an estimated 24,810 adults will be diagnosed with primary
cancerous brain and spinal cord tumors in the United States. Of these, 14,280
will be men and 10,530 will be women. Brain tumors account for 85% to 90% of
all primary central nervous system (CNS) tumors.
·
It is estimated that 5,230 children under 20
will also be diagnosed with a CNS tumor in the US in 2023.
Thelansis’s “Brain Cancer Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Brain Cancer treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Brain Cancer across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Brain Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment